Infinity Pharmaceuticals Provides Additional Information on MARIO-8 Study Evaluating Eganelisib in Combination with the PD-1 Targeted Checkpoint Inhibitor Pembrolizumab (KEYTRUDA ® ) in Patients with Squamous Cell Cancer of the Head and Neck (SCCHN).
